Oculis Publishes Consolidated Q2 Financial Statements and MD&A

Rhea-AI Summary

Oculis, a Swiss-based pharmaceutical company trading under the symbol OCS, has filed its Q2 Consolidated Financial Statements and Management's Discussion and Analysis (MD&A) with the SEC on Form 6-K. This follows an earlier press release announcing the same. The filings provide detailed financial information and management's perspective on the company's performance for the second quarter of 2024. Investors and analysts can now access these documents to gain deeper insights into Oculis's financial health, operational performance, and strategic direction.

News Market Reaction – OCS

+1.51%

+1.51% Session move

In the trading session that priced this news, OCS gained 1.51%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ZUG, Switzerland, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Following the Company‘s press release published earlier today, the Q2 Consolidated Financial Statements and the MD&A, which have now been filed with the SEC on form 6-K, are attached.

Attachments

• Oculis Q2 Unaudited Condensed Consolidated Interim Financial Statements
• Oculis Q2 MD&A

FAQ

What financial documents did Oculis (OCS) file with the SEC for Q2 2024?

Oculis (OCS) filed its Q2 2024 Consolidated Financial Statements and Management's Discussion and Analysis (MD&A) with the SEC on Form 6-K.

When did Oculis (OCS) announce the filing of its Q2 2024 financial documents?

Oculis (OCS) announced the filing of its Q2 2024 financial documents on August 27, 2024, following an earlier press release on the same day.

Where is Oculis (OCS) headquartered?

Oculis (OCS) is headquartered in Zug, Switzerland.

What type of financial statements did Oculis (OCS) file for Q2 2024?

Oculis (OCS) filed Unaudited Condensed Consolidated Interim Financial Statements for Q2 2024.